As of November 6, 2026, 2 holders' latest Schedule 13D or 13G filings report owning 5% or more of Theravance Biopharma, Inc. The largest reported stake is Madison Avenue International LP's, at 17.7%. 5 filings are on record since February 17, 2026 (Schedule 13G/A, August 14, 2026).
Sell to companies like Theravance Biopharma, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: Weiss Asset Management LP · Sole voting: 0 · Shared voting: 0 · Sole dispositive: 0 · Shared dispositive: 0 · SCHEDULE 13D/A, 2026-09-25
- · Reporting person: Madison Avenue International LP · Sole voting: 0 · Shared voting: 9,212,252 · Sole dispositive: 0 · Shared dispositive: 9,212,252 · SCHEDULE 13G/A, 2026-08-14
- · Reporting person: Newtyn Management, LLC · Sole voting: 3,434,191 · Shared voting: 0 · Sole dispositive: 3,434,191 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-08-14
- · Holder: Weiss Asset Management LP · Percent: 14.5% · SCHEDULE 13D/A
- · Holder: Newtyn Management, LLC · Percent: 8.5% · SCHEDULE 13G/A
Theravance Biopharma, Inc. has 5 Schedule 13D or 13G filings on record since 2026-02-17. 2 holders' latest filing reports 5% or more of ordinary share $0.00001 par value. Each figure below is the holder's own, as filed, with the filing linked.
Layoffs on record: 1 filing or notice, latest 2026-03-03 (layoff filings and notices).
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Madison Avenue International LP | 17.7% | 9,212,252 | SCHEDULE 13G/A, 2026-08-14 | 2026-06-30 |
| Newtyn Management, LLC | 6.7% | 3,434,191 | SCHEDULE 13G/A, 2026-08-14 | 2026-06-30 |
| Weiss Asset Management LP | 0% | 0 | SCHEDULE 13D/A, 2026-09-25 | 2026-09-23 |
Holding shares or following this stake? See who's behind Theravance Biopharma, Inc. and the warning signs.
Free to see. No signup.
Keep reading
More on Theravance Biopharma, Inc. and the records around it.
Theravance Biopharma, Inc. elsewhere on the record
- Layoff notices Mar 2026
Companies that share a holder
- Weiss Asset Management LP also filed stake reports on 9 other companies: RE/MAX Holdings, Inc. (Aug 2026), Canaan Inc. (Aug 2026), APARTMENT INVESTMENT & MANAGEMENT CO (May 2026)
- Madison Avenue International LP also filed stake reports on 11 other companies: Ultragenyx Pharmaceutical Inc. (Oct 2026), Graham Holdings Co (Aug 2026), STAAR SURGICAL CO (Aug 2026)
- Newtyn Management, LLC also filed stake reports on 13 other companies: Par Technology Corporation (Aug 2026), QuidelOrtho Corporation (Aug 2026), ZOOZ Strategy Ltd. (Aug 2026)
Watch Theravance Biopharma, Inc.
Get an email when Theravance Biopharma, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Theravance Biopharma, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Theravance Biopharma, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Theravance Biopharma, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
7 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| Madison Avenue International LP | 0 | 9,212,252 | 0 | 9,212,252 | SCHEDULE 13G/A, 2026-08-14 |
| Madison Avenue Partners, LP | 0 | 9,212,252 | 0 | 9,212,252 | SCHEDULE 13G/A, 2026-08-14 |
| EMAI Management, LLC | 0 | 9,212,252 | 0 | 9,212,252 | SCHEDULE 13G/A, 2026-08-14 |
| Madison Avenue GP, LLC | 0 | 9,212,252 | 0 | 9,212,252 | SCHEDULE 13G/A, 2026-08-14 |
| Caraway Jackson Investments LLC | 0 | 9,212,252 | 0 | 9,212,252 | SCHEDULE 13G/A, 2026-08-14 |
| Eli Samaha | 0 | 9,212,252 | 4,175,748 | 9,212,252 | SCHEDULE 13G/A, 2026-08-14 |
| Newtyn Management, LLC | 3,434,191 | 0 | 3,434,191 | 0 | SCHEDULE 13G/A, 2026-08-14 |
| Newtyn TE Partners, LP | 2,212,712 | 0 | 2,212,712 | 0 | SCHEDULE 13G/A, 2026-08-14 |
| Weiss Asset Management LP | 0 | 0 | 0 | 0 | SCHEDULE 13D/A, 2026-09-25 |
| Bip Gp LLC | 0 | 0 | 0 | 0 | SCHEDULE 13D/A, 2026-09-25 |
| Wam Gp LLC | 0 | 0 | 0 | 0 | SCHEDULE 13D/A, 2026-09-25 |
| Andrew M. Weiss | 0 | 0 | 0 | 0 | SCHEDULE 13D/A, 2026-09-25 |
The latest filing identifies Theravance Biopharma, Inc. by CUSIP G8807B106 and gives its principal executive office as Ugland House, South Church Street, George Town (SCHEDULE 13D/A, 2026-09-25).
What the percentages are based on
The following percentage is based on 51,918,754 Ordinary Shares outstanding as of July 31, 2026, as disclosed in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 11, 2026. As of June 30, 2026, the Reporting Persons may be deemed to have beneficially owned approximately 17.7% of the outstanding Ordinary Shares.Madison Avenue International LP, SCHEDULE 13G/A, 2026-08-14
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2026-02-17 | Newtyn Management, LLC | 8.5% | SCHEDULE 13G/A |
| 2026-03-25 | Weiss Asset Management LP | 14.5% | SCHEDULE 13D/A |
| 2026-08-14 | Madison Avenue International LP | 17.7% | SCHEDULE 13G/A |
| 2026-08-14 | Newtyn Management, LLC | 6.7% | SCHEDULE 13G/A |
| 2026-09-25 | Weiss Asset Management LP | 0% | SCHEDULE 13D/A |
Questions about who owns Theravance Biopharma, Inc.
Who owns Theravance Biopharma, Inc.?
On this page, 2 holders' latest ownership filings report 5% or more of Theravance Biopharma, Inc.: Madison Avenue International LP (17.7%, Schedule 13G/A, filed 2026-08-14) and Newtyn Management, LLC (6.7%, Schedule 13G/A, filed 2026-08-14).
Who are the largest shareholders of Theravance Biopharma, Inc.?
By the share each holder's latest filing reports, the largest holders of Theravance Biopharma, Inc. on this page are Madison Avenue International LP (17.7%) and Newtyn Management, LLC (6.7%).
When did Madison Avenue International LP buy into Theravance Biopharma, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Madison Avenue International LP on this page is the Schedule 13G/A, filed 2026-08-14, reporting 17.7%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 5 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Also on the record for Theravance Biopharma, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| June 23, 2026 | Leadership change filing (Form 8-K, Item 5.02) | — | Leadership changes | Source |
Tools for this story
Each opens in a new tab, filled in for Theravance Biopharma, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.